BioCatalyst

Inlexisertib, Ripretinib — catalyst calendar

1 verified catalyst event(s) referencing Inlexisertib, Ripretinib, each linked to its official source. Verified as of 2026-11-01.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in P
Phase 1/2 · GIST
 Deciphera Pharmaceuticals, LLC Inlexisertib, Ripretinib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-01
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.